SCHEMBL6761965

SCHEMBL6761965

CN1CCN(C(=O)c2ccc(Cn3nc(OCc4ccccc4)c4ccccc43)o2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.54
CNR1 P21554 5/20 0.54
ACHE P22303 3/20 0.54
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 1/20 0.46
POLB P06746 2/20 0.45
KMT2A Q03164 1/20 0.43
BCHE P06276 4/20 0.42
LMNA P02545 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GUCY1B2 O75343 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764408 0.84 CNR2 (0.65) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL6763450 0.81 CNR2 (0.58) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL6762827 0.80 SPHK2 (0.50) CNR2CNR1ACHENPC1RAB9A
SCHEMBL6767172 0.78 CNR2 (0.68) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL6767192 0.76 CNR2 (0.51) CNR2CNR1ACHEPOLBLMNA
SCHEMBL6766646 0.75 KDM4E (0.54) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL8007567 0.69 CNR2 (0.68) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL9917403 0.67 CNR2 (0.81) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL9917500 0.66 CNR2 (1.00) CNR2CNR1ACHECYP1A2CYP2D6
SCHEMBL12608904 0.66 CNR2 (0.67) CNR2CNR1ACHECYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US claimed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 CNR2 1561/4885CNR1 1179/4885ACHE 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.